RYTM Q4 2024 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+72.6% YoY

Gross Profit

$38M90.9% margin

Operating Income

-$41M-98.6% margin

Net Income

-$43M-103.5% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

+25.8%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$392M

Total Liabilities

$228M

Stockholders' Equity

$165M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$24M	+72.6%
Gross Profit	$38M	$21M	+81.1%
Operating Income	-$41M	-$41M	+0.0%
Net Income	-$43M	-$42M	-4.0%

Revenue Segments

Product

$104M100%

Geographic Segments

UNITED STATES

$73M100%